A phase II clinical trial (NCT00467506) was conducted to determine the efficacy and safety of anti-CEA × anti-DTPA BsAb and 131I-di-DTPA-indium bivalent hapten in patients with progressive metastatic MTC. Here, CEACAM5 is linked to medullary thyroid gland carcinoma.